falsefalse

CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place - Episode 7

Overcoming Barriers to CAR T Referral in R/R MM

,

Experts discuss the challenges and barriers to early referral for chimeric antigen receptor (CAR) T-cell therapy, including logistical, financial, and patient-related factors that may impact timely access to treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection
    EP. 2: Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT
    EP. 3: Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM
    EP. 4: Strategic Timing for CAR T in R/R MM: The Importance of Early Referral
    EP. 5: Bridging to CAR T in R/R MM: Best Practices
    EP. 6: Explaining CAR T: Key Points for Patient Counseling
    Now Viewing
    EP. 7: Overcoming Barriers to CAR T Referral in R/R MM
    EP. 8: Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM
    EP. 9: Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM
    EP. 10: Exciting Future Horizons for CAR T in MM and Take-Home Messages

    Video content above is prompted by the following:

    • When considering early referral of CAR T, what challenges and/or barriers remain?

    Related Content:

    CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place Video SeriesInsights
    Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC
    45-Year-Old Never-Smoker with Advanced EGFR-Mutant NSCLC and CNS Metastases Treated with the MARIPOSA Regimen
    56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen
    x